Gene Therapy for Malignant Mesothelioma
暂无分享,去创建一个
[1] A. Melcher,et al. A family of bicistronic vectors to enhance both local and systemic antitumor effects of HSVtk or cytokine expression in a murine melanoma model. , 1997, Human gene therapy.
[2] J. Coll,et al. Long-term survival of immunocompetent rats with intraperitoneal colon carcinoma tumors using herpes simplex thymidine kinase/ganciclovir and IL-2 treatments , 1997, Gene Therapy.
[3] B. Robinson,et al. The induction of immune responses to murine malignant mesothelioma by IL‐2 gene transfer , 1997, Immunology and cell biology.
[4] S. Steinberg,et al. Simian virus-40 large-T antigen binds p53 in human mesotheliomas , 1997, Nature Medicine.
[5] D. Altieri,et al. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma , 1997, Nature Medicine.
[6] A. Kinsella,et al. The role of the bystander effect in suicide gene therapy. , 1997, European journal of cancer.
[7] R. Vile,et al. Generation of an anti‐tumour immune response in a non‐immunogenic tumour: HSVtk killing in vivo stimulates a mononuclear cell infiltrate and a Th1‐like profile of intratumoural cytokine expression , 1997, International journal of cancer.
[8] D. Lowrie,et al. In vivo gene therapy of malignant tumours with heat shock protein-65 gene , 1997, Gene Therapy.
[9] A. Bout,et al. Gene therapy of experimental malignant mesothelioma using adenovirus vectors encoding the HSVtk gene , 1997, Gene Therapy.
[10] R. Ramesh,et al. Immune system in suicide-gene therapy , 1997, The Lancet.
[11] J. Wilson,et al. Biology of adenovirus vectors with E1 and E4 deletions for liver-directed gene therapy , 1996, Journal of virology.
[12] J. Wilson,et al. Safety of intrapleurally administered recombinant adenovirus carrying herpes simplex thymidine kinase DNA followed by ganciclovir therapy in nonhuman primates. , 1996, Human gene therapy.
[13] J. Wilson,et al. Treatment of advanced mesothelioma with the recombinant adenovirus H5.010RSVTK: a phase 1 trial (BB-IND 6274). , 1996, Human gene therapy.
[14] G. Viale,et al. Calretinin: a novel immunocytochemical marker for mesothelioma. , 1996, The American journal of surgical pathology.
[15] M. Black,et al. Creation of drug-specific herpes simplex virus type 1 thymidine kinase mutants for gene therapy. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[16] B. O’Malley,et al. Combination gene therapy for oral cancer in a murine model. , 1996, Cancer research.
[17] J. Olsen,et al. Comparison of the effects of three different toxin genes and their levels of expression on cell growth and bystander effect in lung adenocarcinoma. , 1996, Cancer research.
[18] H. Hwang,et al. Treatment of pleural mesothelioma in an immunocompetent rat model utilizing adenoviral transfer of the herpes simplex virus thymidine kinase gene. , 1996, Human gene therapy.
[19] I. Pastan,et al. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[20] G. Fishman,et al. Gap junctions play a role in the 'bystander effect' of the herpes simplex virus thymidine kinase/ganciclovir system in vitro. , 1996, Gene therapy.
[21] P. Vogt,et al. The calcium binding protein calretinin is a selective marker for malignant pleural mesotheliomas of the epithelial type. , 1996, Pathology, research and practice.
[22] A. Eggermont,et al. Intrapleural administration of interleukin 2 in pleural mesothelioma: a phase I-II study. , 1995, British Journal of Cancer.
[23] B. Davidson,et al. Treatment of Experimental Human Mesothelioma Using Adenovirus Transfer of the Herpes Simplex Thymidine Kinase Gene , 1995, Annals of surgery.
[24] H. Hwang,et al. Gene therapy using adenovirus carrying the herpes simplex-thymidine kinase gene to treat in vivo models of human malignant mesothelioma and lung cancer. , 1995, American journal of respiratory cell and molecular biology.
[25] J. Koziol,et al. Cytokine gene therapy with interleukin-2-transduced fibroblasts: effects of IL-2 dose on anti-tumor immunity. , 1995, Human gene therapy.
[26] X. -. Chen,et al. Combination gene therapy for liver metastasis of colon carcinoma in vivo. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[27] Moolten Fl. Drug sensitivity ("suicide") genes for selective cancer chemotherapy. , 1994 .
[28] R. Vile,et al. Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component. , 1994, Cancer research.
[29] R. Grossman,et al. Adenovirus‐mediated gene therapy of experimental gliomas , 1994, Journal of neuroscience research.
[30] J. Douillard,et al. Intrapleural treatment with recombinant gamma‐interferon in early stage malignant pleural mesothelioma , 1994, Cancer.
[31] C. Richards,et al. Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[32] P. Tiberghien. Use of suicide genes in gene therapy , 1994, Journal of leukocyte biology.
[33] J. Pilewski,et al. Successful adenovirus-mediated gene transfer in an in vivo model of human malignant mesothelioma. , 1994, The Annals of thoracic surgery.
[34] B. Davidson,et al. Use of recombinant adenovirus to transfer the herpes simplex virus thymidine kinase (HSVtk) gene to thoracic neoplasms: an effective in vitro drug sensitization system. , 1994, Cancer research.
[35] R. Grossman,et al. Gene therapy for brain tumors: regression of experimental gliomas by adenovirus-mediated gene transfer in vivo. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[36] S. Freeman,et al. The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified. , 1993, Cancer research.
[37] R. Vile,et al. Use of tissue-specific expression of the herpes simplex virus thymidine kinase gene to inhibit growth of established murine melanomas following direct intratumoral injection of DNA. , 1993, Cancer research.
[38] D. Klatzmann,et al. Regression of established macroscopic liver metastases after in situ transduction of a suicide gene. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[39] J. Wilson,et al. Gene therapy: adenovirus vectors. , 1993, Current opinion in genetics & development.
[40] T. Kawabe,et al. Gene transfer of herpes simplex virus type I thymidine kinase gene as a drug sensitivity gene into human lung cancer cell lines using retroviral vectors. , 1993, American journal of respiratory cell and molecular biology.
[41] C. Cicala,et al. SV40 induces mesotheliomas in hamsters. , 1993, The American journal of pathology.
[42] V. Rusch. Pleurectomy/decortication and adjuvant therapy for malignant mesothelioma. , 1993, Chest.
[43] A. Musk,et al. Interleukin-2 and Lymphokine-Activated Killer-Cells in Malignant Mesothelioma , 1993 .
[44] P. Astoul,et al. Intrapleural recombinant IL-2 in passive immunotherapy for malignant pleural effusion. , 1993, Chest.
[45] Z. Ram,et al. In situ retroviral-mediated gene transfer for the treatment of brain tumors in rats. , 1993, Cancer research.
[46] J. Wells,et al. Multiple transduction as a means of preserving ganciclovir chemosensitivity in sarcoma cells carrying retrovirally transduced herpes thymidine kinase genes. , 1992, Cancer letters.
[47] Z. Ram,et al. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. , 1992, Science.
[48] F. Varlet,et al. Activity of intrapleural recombinant gamma‐interferon in malignant mesothelioma , 1991, Cancer.
[49] V. Rusch,et al. Intrapleural cisplatin and cytarabine in the management of malignant pleural effusions: a Lung Cancer Study Group trial. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[50] R. Boehme,et al. Antiviral activity and mechanism of action of ganciclovir. , 1988, Reviews of infectious diseases.
[51] A. Ardizzoni,et al. Intrapleural natural beta interferon in the treatment of malignant pleural effusions. , 1988, Oncology.